Four Analysts Evaluate NeoGenomics: Key Insights You Should Be Aware Of

NeoGenomics Analyst Ratings Overview

• Analyst Sentiment: Recent evaluations from four analysts show a mix of bullish and bearish sentiments towards NeoGenomics, with the latest ratings indicating 2 bullish, 1 somewhat bullish, and 1 indifferent stance. Over the last month, there has been a notable shift towards a more positive outlook.
• Price Target Changes: The average 12-month price target for NeoGenomics has risen to $10.25, reflecting a 6.55% increase from the previous target of $9.62. The high estimate stands at $14.00, while the low is $8.00.

Recent Analyst Actions

• Mike Matson (Needham): Raised his rating to 'Buy' with a new price target of $14.00, up from $8.00.
• David Westenberg (Piper Sandler): Lowered his rating to 'Overweight' with a target of $11.00, down from $12.00.
• Tejas Savant (Morgan Stanley): Adjusted his rating to 'Equal-Weight' with a target of $8.00, reduced from $10.00.
• Mike Matson (Needham): Also lowered his target to $8.00 from $8.50 while maintaining a 'Buy' rating.

Company Overview

• Business Model: NeoGenomics Inc specializes in oncology diagnostic testing and consultative services, operating a network of cancer-focused laboratories in the U.S. and the U.K. The company generates revenue through clinical cancer testing, molecular testing, and oncology data solutions.

Financial Performance Insights

• Market Capitalization: NeoGenomics's market cap is below industry averages, indicating a smaller size relative to competitors, which may affect growth perceptions.
• Revenue Growth: The company reported a revenue growth rate of approximately 10.23% as of June 30, 2025, outperforming many peers in the healthcare sector.
• Net Margin: NeoGenomics boasts a net margin of -24.87%, which, despite being negative, is better than industry averages, suggesting effective cost management.
• Return on Equity (ROE): The ROE stands at -5.18%, indicating challenges in utilizing equity capital effectively.
• Return on Assets (ROA): With an ROA of -3.01%, the company faces difficulties in asset utilization.
• Debt Management: The debt-to-equity ratio is at 0.48, highlighting potential financial strain due to high debt levels.

Importance of Analyst Ratings

• Analyst Role: Analysts provide insights based on extensive research and interactions with company insiders, offering ratings and forecasts for stocks. Their assessments can guide traders, although they are ultimately subjective and based on personal judgment.

Market Outlook

• Future Potential: Analysts are closely monitoring NeoGenomics for potential growth, with some predicting significant upward movement in stock value as market conditions evolve.